Major study investigates which cancer drug poses greater heart risk
NCT ID NCT07283965
Summary
This study aims to understand which of two similar cancer drugs carries a higher risk of causing an irregular heartbeat called atrial fibrillation. Researchers will analyze health records from 15,000 adults with chronic blood cancers who have taken either zanubrutinib or acalabrutinib. The goal is to compare the safety profiles of these two medications to help doctors and patients make more informed treatment choices.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.